ReviewDrugs2014
Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Genomic characterization of XDR Mycobacterium tuberculosis isolates in Argentina (2006-2015).BMC infectious diseases · 2025Article
- Universal Lineage-Independent Markers of Multidrug Resistance inMicroorganisms · 2024Article
- Healthcare seeking behavior and delays in case of Drug-Resistant Tuberculosis patients in Bangladesh: Findings from a cross-sectional survey.PLOS global public health · 2024Article
- Article
- Detection and characterization of mutations in genes related to isoniazid resistance in Mycobacterium tuberculosis clinical isolates from Iran.Molecular biology reports · 2022Article
- A modified decision tree approach to improve the prediction and mutation discovery for drug resistance in Mycobacterium tuberculosis.BMC genomics · 2022Article
- An Epistatic Network DescribesFrontiers in molecular biosciences · 2022Article
- The Epistatic Landscape of Antibiotic Resistance of Different Clades ofAntibiotics (Basel, Switzerland) · 2021Article
- Cumulative Signaling Through NOD-2 and TLR-4 Eliminates theFrontiers in cellular and infection microbiology · 2021Article
- Potential Role of Proteasome Accessory Factor-C in Resistance against Second Line Drugs in Mycobacteria.Journal of laboratory physicians · 2020Article
- Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis.Nature medicine · 2020Article
- Novel Antimycobacterial Compounds Suppress NAD Biogenesis by Targeting a Unique Pocket of NaMN Adenylyltransferase.ACS chemical biology · 2019Article
- What will it take to eliminate drug-resistant tuberculosis?The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2019Article
- Machine Learning Predicts AccuratelyFrontiers in genetics · 2019Article
- Insights into the processes that drive the evolution of drug resistance inEvolutionary applications · 2018Review
- Where is tuberculosis transmission happening? Insights from the literature, new tools to study transmission and implications for the elimination of tuberculosis.Respirology (Carlton, Vic.) · 2018Review
- Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care.The Journal of antimicrobial chemotherapy · 2018Review
- Multi-clonal evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium tuberculosis in a high-prevalence setting of Papua New Guinea for over three decades.Microbial genomics · 2018Article
- Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.PloS one · 2018Article
- Comparative Genome Analysis of 2Evolutionary bioinformatics online · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Drug-resistant tuberculosis is a growing threat to global public health. Recent efforts to understand the evolution of drug resistance have shown that changes in drug-target interactions are only the first step in a longer adaptive process. The emergence of transmissible drug-resistant Mycobacterium tuberculosis is the result of a multitude of additional genetic mutations, many of which interact, a phenomenon known as epistasis. The varied effects of these epistatic interactions include compensating for the reduction of the biological cost associated with the development of drug resistance, increasing the level of resistance, and possibly accommodating broader changes in the physiology of resistant bacteria. Knowledge of these processes and our ability to detect them as they happen informs the development of diagnostic tools and better control strategies. In particular, the use of whole genome sequencing combined with surveillance efforts in the field could provide a powerful instrument to prevent future epidemics of drug-resistant tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.